Overexpression pattern, function, and clinical value of proteasome 26S subunit non-ATPase 6 in hepatocellular carcinoma

Table 1 Association between clinicopathological information and proteasome 26S subunit non-ATPase 6 protein expression levels in inhouse hepatocellular carcinoma tissue samples

Clinicopathological Features		PSMD6 protein expression
		n	Mean	SD	t (t-test) or F (ANOVA)	P value
Gender	Male	82	9.06	2.94	-0.93	0.36
	Female	17	9.79	2.91
Age	> 60 years	28	8.77	2.99	-0.89	0.38
	≤ 60 years	71	9.35	2.92
Tumour necrosis	Yes	34	9.08	2.88	-0.26	0.80
	No	65	9.24	2.99
Tumour recurrence	Yes	4	9.00	3.60	-0.13	0.90
	No	95	9.20	2.93
Number of lesions	1	91	9.20	2.88	0.09	0.93
	> 1	8	9.10	3.73
Satellite nodules	Yes	9	9.29	2.04	0.11	0.92
	No	90	9.18	3.02
Vascular invasion	M0	50	8.79	3.07	1.34	0.27
	M1	35	9.38	2.82
	M2	13	10.22	2.60
Lymph node invasion	Yes	10	9.88	1.92	1.12	0.29
	No	89	9.11	3.03
Hepatitis grade	G0	6	8.07	3.49	0.58	0.63
	G1	36	8.93	2.86
	G2	54	9.44	3.00
	G3	3	10.00	1.74
Liver fibrosis grading	S1	9	9.87	2.71	0.23	0.88
	S2	19	8.88	3.72
	S3	12	9.03	3.41
	S4	52	9.15	2.59
T stage	T1	45	8.75	3.04	1.10	0.34
	T2	44	9.65	2.87
	T3	9	8.84	2.69
N stage	N0	96	9.18	2.97	-0.09	0.93
	N1	3	9.33	2.31
HBV	Positive	86	9.02	2.96	-1.44	0.15
	Negative	13	10.28	2.65
HCV	Positive	5	6.32	3.65	-2.29	0.02
	Negative	94	9.34	2.84
AFP	> 400 ng/mL	41	9.35	2.91	0.45	0.65
	< 400 ng/mL	58	9.08	2.98
BCLC staging	A	81	9.27	2.93	0.15	0.86
	B	13	8.80	3.04
	C	3	9.33	2.31

HBV: Hepatitis B virus; HCV: Hepatitis C virus; PSMD6: Proteasome 26S subunit non-ATPase 6; AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer.